Kazim Secgen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kazim Secgen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Fatih Ezgu
Division of Pediatric Genetics, Department of Pediatrics Faculty of Medicine, Gazi University Ankara Türkiye
2 shared publications - Aslı İnci
Department of Pediatric Nutrition and Metabolism, School of Medicine, Gazi University, Ankara 06500, Türkiye
1 shared publication - Avniye Kübra Baskın
Department of Pediatric Immunology and Allergy, Gazi University Faculty of Medicine, Ankara, Turkey
1 shared publication - Ayhan Pektaş
Afyonkarahisar Health Sciences University / Türkiye
1 shared publication - Ergün Barış Kaya
Department of Cardiology Hacettepe University Faculty of Medicine Ankara Turkey
1 shared publication - Fatma Hayvacı Canbeyli
Division of Pediatric Cardiology, Faculty of Medicine, Gazi University, ANKARA, TÜRKIYE
1 shared publication
Latest Publications
- 8 October 2026
- Published by Wiley in Clinical Genetics
A Homozygous ALCAM–CBLB Deletion at 3q13.11‐q13.12 Defines a Candidate Novel Oculo‐Skeletal‐Immune Contiguous Gene Deletion Syndrome
To our knowledge, we report the first combined homozygous deletion of ALCAM and CBLB at 3q13.11‐q13.12. The patient, a 14‐year‐old boy born to consanguineous parents, had a multisystem phenotype with severe congenital ocular and craniofacial anomalies, early‐onset osteoporosis, progressive scoliosis, growth failure, congenital heart defect, humoral immunodeficiency, and chronic inflammatory findings. SNP array identified a 2.5‐Mb homozygous deletion spanning ALCAM and CBLB , and expression studies confirmed complete absence of ALCAM and CBLB expression. Whole‐exome sequencing did not identify an alternative molecular diagnosis. The clinical presentation is likely attributable to combined ALCAM and CBLB loss. Previous animal‐model studies support interpretation of the individual phenotypic components by linking loss of these genes to craniofacial developmental abnormalities, skeletal findings, and immune dysregulation. We propose that this deletion may represent a candidate novel contiguous gene deletion syndrome. This case is the first human phenotype associated with complete ALCAM loss in a contiguous deletion and expands the clinical spectrum associated with disruption of ALCAM and CBLB .
- 8 October 2026
- Published by Wiley in Clinical Genetics
A Homozygous ALCAM–CBLB Deletion at 3q13.11‐q13.12 Defines a Candidate Novel Oculo‐Skeletal‐Immune Contiguous Gene Deletion Syndrome
To our knowledge, we report the first combined homozygous deletion of ALCAM and CBLB at 3q13.11‐q13.12. The patient, a 14‐year‐old boy born to consanguineous parents, had a multisystem phenotype with severe congenital ocular and craniofacial anomalies, early‐onset osteoporosis, progressive scoliosis, growth failure, congenital heart defect, humoral immunodeficiency, and chronic inflammatory findings. SNP array identified a 2.5‐Mb homozygous deletion spanning ALCAM and CBLB , and expression studies confirmed complete absence of ALCAM and CBLB expression. Whole‐exome sequencing did not identify an alternative molecular diagnosis. The clinical presentation is likely attributable to combined ALCAM and CBLB loss. Previous animal‐model studies support interpretation of the individual phenotypic components by linking loss of these genes to craniofacial developmental abnormalities, skeletal findings, and immune dysregulation. We propose that this deletion may represent a candidate novel contiguous gene deletion syndrome. This case is the first human phenotype associated with complete ALCAM loss in a contiguous deletion and expands the clinical spectrum associated with disruption of ALCAM and CBLB .
- Open Access
- 4 April 2025
- Published by Springer Nature in Pediatric Cardiology
- Vol. 47 (2) , 821-829
The Role of Genetics in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension
Pulmonary arterial hypertension associated with congenital heart disease (APAH-CHD) is a severely progressive condition with complex pathogenesis. The aim of this study was to evaluate the contribution of genetic variants to the development of PAH in patients with APAH-CHD. Fifteen children and twenty-seven adults diagnosed with APAH-CHD were enrolled. Targeted next-generation sequencing was performed on PAH-associated genes ( ABCC8 , ACVRL1 , AQP1 , ATP13A3 , BMPR2 , CAV1 , GDF2 , GGCX , EIF2AK4 , ENG , KCNK3 , KDR , KLK1 , SMAD1 , SMAD4 , SMAD9 , SOX17 , TBX4 , TET2 ). A total of 21 distinct variants across 11 different genes were detected in 17 of the 42 patients. ( ABCC8 = 2, ACVRL1 = 1, ATP13A3 = 2, BMPR2 = 4, GGCX = 1, EIF2AK4 = 2, ENG = 1, KDR = 3, SMAD1 = 1, SMAD9 = 1, TET2 = 3). Five of the patients with the mutation were under the age of 18, and 12 patients were adults. The most common CHD in patients with detected variants was VSD. PAH-related genetic variants were not uncommon in APAH-CHD patients. Our study identified 12 novel variants that may help to understand the genetic basis of APAH-CHD. Trial Registration The study has been registered on ClinicalTrials.gov with the identification number NCT05550389.
- 4 April 2025
- Published by Springer Nature in Pediatric Cardiology
- Vol. 47 (2) , 821-829
Open AccessThe Role of Genetics in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension
Pulmonary arterial hypertension associated with congenital heart disease (APAH-CHD) is a severely progressive condition with complex pathogenesis. The aim of this study was to evaluate the contribution of genetic variants to the development of PAH in patients with APAH-CHD. Fifteen children and twenty-seven adults diagnosed with APAH-CHD were enrolled. Targeted next-generation sequencing was performed on PAH-associated genes ( ABCC8 , ACVRL1 , AQP1 , ATP13A3 , BMPR2 , CAV1 , GDF2 , GGCX , EIF2AK4 , ENG , KCNK3 , KDR , KLK1 , SMAD1 , SMAD4 , SMAD9 , SOX17 , TBX4 , TET2 ). A total of 21 distinct variants across 11 different genes were detected in 17 of the 42 patients. ( ABCC8 = 2, ACVRL1 = 1, ATP13A3 = 2, BMPR2 = 4, GGCX = 1, EIF2AK4 = 2, ENG = 1, KDR = 3, SMAD1 = 1, SMAD9 = 1, TET2 = 3). Five of the patients with the mutation were under the age of 18, and 12 patients were adults. The most common CHD in patients with detected variants was VSD. PAH-related genetic variants were not uncommon in APAH-CHD patients. Our study identified 12 novel variants that may help to understand the genetic basis of APAH-CHD. Trial Registration The study has been registered on ClinicalTrials.gov with the identification number NCT05550389.